CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

NCT03370159 | Withdrawn Phase 1 FDA Drug

• 4 other identifiers: IRB00044399NCI-2017-02010CCCWFU 62217P30CA012197
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This phase I/II trial studies the side effects and best dose of 6,8-bis(benzylthio)octanoic acid (CPI-613) when given together with docetaxel and to see how well they work in treating patients with stage IIIB or IV non-small cell lung cancer. Drugs used in chemotherapy, such as CPI-613 and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Conditions

Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7

Outcome Measures

Primary Outcomes (2)

• Phase II dose of 6,8-bis(benzylthio)octanoic acid (CPI-613) when administered in combination with a standard dose of docetaxel (Phase 1)

  Up to 18 weeks

• Response rate defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Phase 2)

  Will estimate the proportion of patients with a response (complete response + partial response) and calculate a 95% confidence interval for this measure.

  Up to 2 years

Secondary Outcomes (4)

• Median progression-free survival (PFS)

  From the start of treatment to the time of progression or death, assessed up to 2 years

• Number and degree of adverse events under the experimental therapy regimens graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03

  Up to 30 days after the last study drug is administered

• Overall survival (OS)

  From the start of treatment to date of death, assessed up to 2 years

• Progression-free survival (PFS)

  From the start of treatment to the time of progression or death, assessed at 27 weeks

Study Arms (1)

Treatment (CPI-613, docetaxel)

EXPERIMENTAL

Patients receive CPI-613 IV over 2 hours on days 1 and 3, and docetaxel IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients that achieve stable disease after 6 courses then receive CPI-613 alone on days 1and 3. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Drug: 6,8-Bis(benzylthio)octanoic Acid; Drug: Docetaxel; Other: Pharmacological Study

Interventions

6,8-Bis(benzylthio)octanoic Acid DRUG

Given IV

Also known as: Alpha-Lipoic Acid Analogue CPI-613, CPI 613, CPI-613

Treatment (CPI-613, docetaxel)

Docetaxel DRUG

Given IV

Also known as: Docecad, RP56976, Taxotere, Taxotere Injection Concentrate

Treatment (CPI-613, docetaxel)

Pharmacological Study OTHER

Correlative studies

Treatment (CPI-613, docetaxel)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have histologically or cytologically confirmed stage IIIB or IV NSCLC with radiographic proof of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
• Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
• Life expectancy of \>= 3 months
• Patients must have received previous systemic therapy to include: a regimen of chemotherapy, immunotherapy including anti-PDL or anti-PD-L1 therapies, combined chemotherapy and immunotherapy, provided treatment was discontinued \>= 2 weeks prior to initiation of treatment on the present protocol
• Absolute neutrophil count \>= 1,500/uL
• Platelets \>= 100,000/uL
• Total bilirubin within normal institutional limits
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) within institutional upper limit of normal
• International normalized ratio (INR) =\< 1.5 x upper limit of normal (ULN)
• Prothrombin time (PT) =\< 1.5 x ULN
• Activated partial thromboplastin time (aPTT) =\< 1.5 x ULN or within therapeutic range if receiving anticoagulant therapy OR
• Creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal
• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study through 30 days after the last dose of study medication; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
• Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document (either directly or via a legally authorized representative)

You may not qualify if:

• Patients who have had immunotherapy or tyrosine kinase inhibitor (TKI) therapy within two weeks prior to entering the study
• Radiotherapy or prior systemic chemotherapy within 2 weeks
• Patients who have been treated with more than one chemotherapy regimen, immunotherapy regimen or chemotherapy/immunotherapy regimen for metastatic non-small cell lung cancer
• Adverse events resulting from previous therapies have not recovered to grade 1 or less
• Patients may not be receiving any other investigational agents
• Patients with untreated, symptomatic brain metastases should be excluded from this clinical trial (patients with asymptomatic brain metastases amenable to treatment with Gamma Knife radiosurgery \["GKRS"\] are eligible and may receive GKRS while on protocol)
• Lactating females
• Patients with EGFR, ALK or ROS-1 mutations who are eligible for treatment with a TKI and who have not received such treatment
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to CPI-613 or docetaxel
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CPI-613
• Any condition that may, in the opinion of the investigator, compromise the safety of the patient

Sponsors & Collaborators

• Wake Forest University Health Sciences: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Comprehensive Cancer Center of Wake Forest University

Winston-Salem, North Carolina, 27157, United States

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

devimistat; Docetaxel

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Study Officials

• Stefan Grant

  Wake Forest University Health Sciences

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 4, 2017
• First Posted: December 12, 2017
• Study Start: June 1, 2018
• Primary Completion: March 1, 2019
• Study Completion: March 1, 2020
• Last Updated: August 1, 2018

Record last verified: 2018-07

Locations

US (1)